(HealthDay News) — Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures, ...

The approval was based on data from the BLUE-C trial, which assessed the sensitivity and specificity of the Cologuard Plus test vs FIT in asymptomatic adults scheduled for screening colonoscopy.

The alert follows an announcement from the US DOJ regarding the indictment of 18 individuals who operated a network of fake online pharmacies and pill mills.

The US Department of Health and Human Services has set a goal that at least 95% of children in kindergarten get 2 doses of the measles-mumps-rubella (MMR) vaccine, a threshold that helps prevent ...

(HealthDay News) — Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active ...

(HealthDay News) — Harmful diagnostic errors (DEs) occur in an estimated one of every 14 hospitalized general medicine patients, according to a study published online Oct. 1 in BMJ Quality & Safety.

The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum glucocorticoid regulated kinase 1 (SGK1) inhibitor, for the treatment of long QT syndrome ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to navenibart for the treatment of hereditary angioedema (HAE).

The first generic version of Sandostatin ® LAR Depot is now available from Teva Pharmaceuticals. Teva’s Octreotide Acetate for Injectable Suspension is indicated for treatment in patients who ...